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COMMENTARY
CACHD1: A new activity-modifying protein for voltage-gated calcium channels
Gary J. Stephens and Graeme S. Cottrell
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ARTICLE HISTORY Received 20 March 2019; Accepted 22 March 2019
Understanding the mechanisms that regulate the traf-
ficking and expression of voltage-gated calcium chan-
nels (VGCCs) at presynaptic and potentially
postsynaptic plasma membrane microdomains is of
paramount importance. VGCCs are subdivided into
two main families: high voltage-activated calcium
channels (HVACCs) and low voltage-activated cal-
cium channels (LVACCs) (reviewed [1]). HVACCs
comprise CaV1.1–4 (L-type current), CaV2.1 (P/
Q-type current), CaV2.2 (N-type current) and CaV
2.3 (R-type current) VGCCs, whereas LVACCs com-
prise the CaV3 (T-type current) family. The expres-
sion, assembly, localization and biophysical properties
of HVACCs can be modulated by α2δ and β auxiliary
subunits. However, the modulation of CaV3 channels
by other proteins has remained less well defined. α2δ
and β subunits are not considered to be auxilliary
subunits for CaV3 subunits and consensus opinion is
that CaV3 can form fully functional channels alone
(reviewed [2]). We have recently identified CACHD1
(Ca2+ channel and chemotaxis receptor (cache)
domain containing protein 1), a protein with struc-
tural similarities to the α2δ family, as a modulator of
CaV3 VGCC activity in expression systems and in
native neurons [3]. Our study adds to other recently
defined modulators of CaV3 subunits which include
endogenous molecules such as the actin binding pro-
tein kelch-like 1 (KLHL1), the Stac adaptor protein 1
(Stac1), the endoplasmic reticulum integral mem-
brane protein, calnexin and the ubiquitin-specific
protease, USP5 (reviewed [4]).
Primary sequence analysis reveals that although
CACHD1 has limited sequence identity to α2δ sub-
units, it similarly contains a VWA (von Willebrand
Factor A) domain and putative bacterial
chemosensory-like cache domains (Figure 1).
However, there are a number of important differences
compared to α2δ subunits that will potentially affect
CACHD1 function. For example, CACHD1 contains
fewer predicted glycosylation sites, a variant metal
ion-dependent adhesion site (MIDAS) motif
(D234xGxS) within the VWA domain and a variant
gabapentin binding site (R213-S-R). Of potential
importance, CACHD1 is predicted to be a single
transmembrane protein with a large intracellular
C-terminal tail, unlike α2δ, which is reportedly
a glycophosphatidylinositol (GPI)-anchored protein
(reviewed [2]). In our study, we demonstrated that
CACHD1 promoted the cell surface localization of
CaV3.1 in a heterologous expression system [3].
Furthermore, using proximity ligation assays, we
showed that CACHD1 and CaV3.1 are <40 nm apart
at the cell surface, supporting the formation of
CACHD1∙CaV3.1 complexes at the plasma mem-
brane. Our electrophoretic analyses indicated that
CACHD1migrated slower than its predicted molecu-
lar mass of 142 kDa, migrating at approximately
~170 kDa, possibly indicating post-translational gly-
cosylation. Human CACHD1 was shown to cause
clear effects on human CaV3.1, CaV3.2 and CaV3.3
subunits, increasing peak current density with
a corresponding increase in maximal conductance.
In contrast, expression of α2δ1 had no effect on
T-type current under the same conditions. CACHD1
increased the open probability of the CaV3.1 channel,
pointing to mechanistic effects on the α1 subunit. We
further demonstrated functional effects of CACHD1
on native T-type current in rat hippocampal neurons.
CACHD1 transfected neurons fired at a higher fre-
quency than control neurons, an effect that was
CONTACT Gary J. Stephens g.j.stephens@reading.ac.uk
Autocommentary to: Cottrell GS, Soubrane CH, Hounshell JA, Lin H, Owenson V, Rigby M, Cox PJ, Barker BS, Ottolini M, Ince S, Bauer, CC, Perez-Reyes E, Patel
MK, Stevens EB, Stephens GJ (2018) CACHD1 is an α2δ-like protein that modulates CaV3 voltage-gated calcium channel activity J Neurosci 38:9186-9201.
CHANNELS
http://dx.doi.org/10.1080/19336950.2019.1600968
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
prevented by the selective T-type current blocker
TTA-P2. Furthermore, CACHD1 caused
a significant increase in rebound firing frequency,
a property mediated predominantly by T-type cur-
rent; TTA-P2 similarly reversed this effect. Together,
these data support a role for CACHD1 in increasing
neuronal T-type current, which in turn promotes an
increase in action potential firing frequency and neu-
ronal excitability. The future study of neurons from
CACHD1 knockout mice will further advance knowl-
edge of the physiological role of CACHD1.
A subsequent report has also identified a role
for CACHD1 as a modulator of other VGCC sub-
types, reporting effects on CaV2.2 [5]. Together,
these studies suggest that CACHD1 may have
broader therapeutic potential. However, although
CACHD1 caused a significant increase in CaV2.2
current, this modulation was not as profound as
seen for α2δ1; indeed, co-expression of CACHD1
caused a reduction in α2δ1-mediated actions on
CaV2.2. These data indicate that CACHD1 may
have a dominant negative-like effect on N-type
calcium current and led to the suggestion that
CACHD1 and α2δ1 may compete for the same
structural motif on CaV2.2 [5], unlike the situation
for CaV3 subunits. In our original studies, we did
not detect any significant increase in Ca2+ current
for human CaV2.2 co-expressed with human
CACHD1 [6], in contrast to effects reported for rat
CaV2.2 with zebrafish or rat CACHD1 [5]. Of
further interest was that these CACHD1 ortholo-
gues had no effect on rat CaV2.1 [5]. Therefore, it
may be that CACHD1 effects are dependent on the
species of both CACHD1 and the α1 subunit.
The α2δ MIDAS motif (DxSxS) within its VWA
domain plays a major role in their modulation of
VGCC function (reviewed [2]). Approximately 46%
of VWA domain-containing proteins contain
a conserved MIDAS motif [7]. CACHD1 has
a variant MIDAS motif (D234xGxS). Of functional
importance, structural studies of VWA domains and
biochemical analysis of a family of proteins called
copines revealed that a perfectly conserved MIDAS
motif is not required for metal ion binding [7]. Due
to the difficulties of predicting non-contiguous
structural motifs, such as cache domains, from
Figure 1. Schematic comparison of the major domains and structural motifs of α2δ1 and CACHD1. (Left) α2δ1 is translated as
a single polypeptide chain that is proteolytically processed into two chains (α2 and δ), which are covalently connected by a disulphide
bridge. The δ chain is further processed to tether the protein to the plasma membrane, reportedly via a glycophosphatidylinositol anchor
(reviewed [2]). Crystallographic studies reveal that the large extracellular facing portion of α2δ1 contains a von Willebrand Factor A (VWA)
domain and four cache domains [9]. Within the VWA domain, α2δ1 possesses a consensus metal ion-dependent adhesion site (MIDAS)
motif that is important for its interaction with pore-forming α1 subunits. (Right) CACHD1 is a single polypeptide chain with a large
extracellular N-terminal domain, a single transmembrane domain and an intracellular C-terminal tail. Similar to α2δ1, the extracellular
region of CACHD1 contains a single VWA domain. Currently, CACHD1 has two predicted cache domains and contains a variant MIDAS
motif within its VWA domain.
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primary sequences, it remains undetermined if the
downstream Thr and Asp residues in human
CACHD1 contribute to a conserved MIDAS motif.
However, one could speculate, based on our preli-
minary sequence alignments, that these residues are
Thr311 and Asp338. Mutation of the Asp and Ser
residues to Ala (AxAxA) in the α2δ1 MIDAS motif
caused disruption of the interaction between α2δ1
and CaV2.2 and this interaction was also prevented
by mutation of Asp122 to Ala on CaV2.2 [5]; surpris-
ingly, the D122A mutation did not prevent
CACHD1-mediated enhancement of CaV2.2 cur-
rents. This data may indicate that CACHD1 does
not interact with CaV2.2 in exactly the same way as
α2δ1. Future biochemical and electrophysiological
studies involving mutated forms of the CACHD1
variant MIDAS motif will shed light on its role in
the regulation of the function of both CACHD1 and
VGCCs. The electrophoretic mobility of rat
CACHD1 was increased to its predicted level by
treatment of whole cell lysates with the N-linked
deglycosylating enzyme, PNGase F, indicating that
rat CACHD1 is modified by N-linked glycosylation
[5]. This study highlighted seven high potential
N-linked glycosylation sites on rat CACHD1.
Similar sequence analysis of human CACHD1
reveals one very high probability site (Asn145), five
other high probability Asn residues, with an addi-
tional three lower potential sites. Future experimen-
tation will reveal precisely which residues are
glycosylated and the role of glycosylation in the
function of human CACHD1.
To date, CACHD1 and the α2δ isoforms are the
only mammalian proteins known to contain bac-
terial chemosensory-like cache domains. Cache
domains are the most important extracellular sen-
sors in prokaryotes (reviewed [8]) and may repre-
sent potential drug targets. The current predicted
CACHD1 structure, including two predicted cache
domains, is based on extant Uniprot data
(Q5VU97). For α2δ1, the initial description of
a single cache domain (Uniprot data, P54289)
has been revised to two and most recently to
four domains following the latest crystal structure
at 3.6 Å [9]. A similar crystal structure will be
required to determine the number of cache
domains in CACHD1, but the presence of multiple
cache domains adds another dimension to the
possible functionality of both α2δ and CACHD1.
With regard to our recent work, CACHD1 is
predicted to act mechanistically to increase CaV3
channel open probability and promote T-type cur-
rents. Such physiological actions may have impli-
cations in targeting diseases involving aberrant
neuronal firing. In particular, CaV3 channels have
been proposed as therapeutic targets to combat
pain and epilepsy (reviewed [4]). It is of particular
interest that CACHD1 transcripts are highly
expressed in mouse dorsal root ganglia [10], key
transducers of nociceptive information. However,
the therapeutic potential of CaV3-targeting drugs
remains largely unrealized, as clinical drugs such
as ethosuximide lack CaV3 selectivity and an ear-
lier agent, mibefradil, was withdrawn due to ser-
ious drug interaction issues. It will be of interest to
identify the functions of the domains and
sequence motifs present in CACHD1 responsible
for its effects on T-type currents and the sequences
within CaV3 channels that may participate in the
interaction with CACHD1. Targeting proteins
such as CACHD1 that modulate CaV3 function
may provide an attractive alternative to the direct
blocking of the α1 subunit pore and we propose
that CACHD1 represents an important new pro-
tein with excellent potential for future therapeutic
targeting.
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